GH Secretagogues
CJC-1295
Also published as Modified GRF (1-29), CJC-1295 DAC, Tetrasubstituted GRF(1-29), Sermorelin analogue
A modified analogue of the first 29 residues of growth hormone releasing hormone. Two different products are sold under this one name, and confusing them is the most common technical error in the wholesale peptide trade.
Where it came from
Developed by ConjuChem in Canada. The DAC technology was the company's core platform, designed to bind circulating albumin and extend half life from minutes to days.
What the literature examines
- GHRH receptor binding and pulsatile growth hormone release
- Albumin conjugation and extended half life pharmacokinetics
- GH and IGF-1 elevation in healthy human volunteers
- Growth hormone deficiency, in early clinical work
State of the evidence
Human pharmacokinetic and endocrine data exists for the DAC version. A clinical programme was halted and the compound was not registered.
What a buyer should know
CJC-1295 without DAC is not CJC-1295. It is modified GRF (1-29), a tetrasubstituted GHRH fragment with a half life measured in minutes. The DAC version carries a maleimidopropionic acid linker that binds albumin and lasts days. They are different molecules with different pharmacokinetics sold under one name, and your customers will not know that unless you tell them. Both are on the WADA prohibited list under S2.
Handling and stability
Lyophilised, water soluble. Cold storage once reconstituted.
Read it yourself
We do not publish a curated citation list, because a hand picked list of papers is a sales tool. These links run a live query against the public databases, so you see everything, including the results that do not suit us.
Supplied for laboratory research use only. Nothing on this page is a dose, a protocol or a claim of effect in humans, and nothing here is medical advice. Read our research use policy.